Scholarlink

<p>Glioblastoma (GBM), a highly aggressive malignant brain tumor, leads to poor clinical outcomes and low long-term survival rates. Using bioinformatics approaches, we analyzed single-cell RNA sequencing (scRNA-seq) data (GSE273274) from glioma patient samples in this study. It was found that mesenchymal-like (MES-like) cells in the GBM center (GC) significantly facilitated GBM’s aggressive spread and microenvironmental reprogramming. Further analysis on MES-like cells suggested that these cells may participate in the progression from glial differentiation to invasive metastasis. Differential expression analysis, univariate Cox regression, and LASSO regression identified <i>COL22A1</i> as a key gene. <i>COL22A1</i> was highly expressed in GC compared to GBM surrounding tissue (GS) and exhibited potential connection to aberrant phosphatidylinositol 3-kinase (PI3K) signaling activation, indicating that <i>COL22A1</i> may act as a potential regulator of GBM, promoting malignant processes such as proliferation, apoptosis resistance, migration, and invasion. In vitro experiments showed that <i>COL22A1</i> overexpression (<i>COL22A1</i>-OE) U-87 cells exhibited enhanced proliferation, viability, migration, and invasion. Moreover, immunoblotting of BCL-2 and BAX revealed that <i>COL22A1</i>-OE increased resistance to apoptosis in U-87 cells. However, all these effects were reversed upon silencing of <i>COL22A1</i>, which suggests <i>COL22A1</i> could be a promising new target for GBM therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Malignant progression of MES-like cells mediated by COL22A1 in the spatial heterogeneity of glioblastoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月6日

查看全文
  • Guangyuan Chen,
  • Zhonghua Fu,
  • Xulin He,
  • Zhaoli Shen

摘要

Glioblastoma (GBM), a highly aggressive malignant brain tumor, leads to poor clinical outcomes and low long-term survival rates. Using bioinformatics approaches, we analyzed single-cell RNA sequencing (scRNA-seq) data (GSE273274) from glioma patient samples in this study. It was found that mesenchymal-like (MES-like) cells in the GBM center (GC) significantly facilitated GBM’s aggressive spread and microenvironmental reprogramming. Further analysis on MES-like cells suggested that these cells may participate in the progression from glial differentiation to invasive metastasis. Differential expression analysis, univariate Cox regression, and LASSO regression identified COL22A1 as a key gene. COL22A1 was highly expressed in GC compared to GBM surrounding tissue (GS) and exhibited potential connection to aberrant phosphatidylinositol 3-kinase (PI3K) signaling activation, indicating that COL22A1 may act as a potential regulator of GBM, promoting malignant processes such as proliferation, apoptosis resistance, migration, and invasion. In vitro experiments showed that COL22A1 overexpression (COL22A1-OE) U-87 cells exhibited enhanced proliferation, viability, migration, and invasion. Moreover, immunoblotting of BCL-2 and BAX revealed that COL22A1-OE increased resistance to apoptosis in U-87 cells. However, all these effects were reversed upon silencing of COL22A1, which suggests COL22A1 could be a promising new target for GBM therapy.